Santa Monica Partners LP bought a new stake in Simulations Plus, Inc. (NASDAQ:SLP) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 33,063 shares of the technology company’s stock, valued at approximately $532,000. Simulations Plus accounts for approximately 0.5% of Santa Monica Partners LP’s portfolio, making the stock its 19th biggest position. Santa Monica Partners LP owned approximately 0.19% of Simulations Plus at the end of the most recent quarter.
Several other institutional investors have also made changes to their positions in the company. Bank of Montreal Can purchased a new stake in shares of Simulations Plus in the 4th quarter worth about $104,000. The Manufacturers Life Insurance Company raised its stake in Simulations Plus by 13.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 8,923 shares of the technology company’s stock valued at $110,000 after purchasing an additional 1,085 shares during the last quarter. New York State Common Retirement Fund acquired a new position in Simulations Plus in the 2nd quarter valued at about $143,000. Strs Ohio raised its stake in Simulations Plus by 196.9% in the 4th quarter. Strs Ohio now owns 9,500 shares of the technology company’s stock valued at $152,000 after purchasing an additional 6,300 shares during the last quarter. Finally, Algert Global LLC acquired a new position in Simulations Plus in the 4th quarter valued at about $175,000. 33.93% of the stock is currently owned by institutional investors and hedge funds.
Shares of Simulations Plus, Inc. (NASDAQ:SLP) traded down $0.50 during midday trading on Tuesday, reaching $15.90. The company’s stock had a trading volume of 23,958 shares, compared to its average volume of 52,661. Simulations Plus, Inc. has a 1 year low of $10.05 and a 1 year high of $17.45. The firm has a market capitalization of $276.68, a price-to-earnings ratio of 44.44 and a beta of -0.63.
Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings results on Tuesday, January 9th. The technology company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.01. Simulations Plus had a return on equity of 24.56% and a net margin of 23.78%. The company had revenue of $7.07 million for the quarter, compared to analyst estimates of $6.57 million. research analysts anticipate that Simulations Plus, Inc. will post 0.4 EPS for the current year.
In related news, Chairman Walter S. Woltosz sold 18,500 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $16.13, for a total transaction of $298,405.00. Following the completion of the transaction, the chairman now owns 5,482,916 shares of the company’s stock, valued at $88,439,435.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 55,500 shares of company stock valued at $899,655 in the last ninety days. Company insiders own 33.45% of the company’s stock.
A number of research firms have weighed in on SLP. BidaskClub upgraded Simulations Plus from a “hold” rating to a “buy” rating in a report on Saturday, February 24th. Zacks Investment Research upgraded Simulations Plus from a “sell” rating to a “hold” rating in a research note on Wednesday, January 24th.
COPYRIGHT VIOLATION NOTICE: This piece was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/03/13/santa-monica-partners-lp-invests-532000-in-simulations-plus-inc-slp.html.
Simulations Plus Profile
Simulations Plus, Inc (Simulations Plus) develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The Company offers five software products for pharmaceutical research. ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200,000 compounds per hour.
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.